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Aliaksandr A. Yarmishyn* and Igor V. Kurochkin*
Department of Genome and Gene Expression Data Analysis, Bioinformatics Institute, Agency for Science, Technology and
Research, Singapore, Singapore
Long noncoding RNAs (lncRNAs) are a novel class of RNA molecules defined as
transcripts longer than 200 nucleotides that lack protein coding potential. They
constitute a major, but still poorly characterized part of human transcriptome, however,
evidence is growing that they are important regulatory molecules involved in various
cellular processes. It is becoming increasingly clear that many lncRNAs are deregulated
in cancer and some of them can be important drivers of malignant transformation. On
the one hand, some lncRNAs can have highly specific expression in particular types of
cancer making them a promising tool for diagnosis. The expression of other lncRNAs
can correlate with different pathophysiological features of tumor growth and with patient
survival, thus making them convenient biomarkers for prognosis. In this review we outline
the current state of knowledge about the fast growing field of application of lncRNAs as
tumor biomarkers.
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Introduction
The development of high resolution microarray and genomewide sequencing technologies allowed
comprehensive characterization of mammalian transcriptomes. The main conclusion from the
pioneering in-depth transcriptome studies performed by FANTOM (Functional Annotation Of
Mouse genome) and ENCODE (Encyclopedia of DNA Elements) consortia was discovery of the
pervasive transcription of the mouse and human genomes with protein coding mRNAs constitut-
ing only a minor fraction of the transcribed sequences (Okazaki et al., 2002; Carninci et al., 2005;
Birney et al., 2007). The most recent data from ENCODE consortium indicates that around 70%
of human genome is transcribed, generating a vast range of noncoding RNAs (Djebali et al., 2012).
Based on transcript size noncoding RNAs are classiﬁed into small noncoding RNAs (<200 nt) and
long noncoding RNAs (lncRNAs; >200 nt). Small noncoding RNAs, particularly miRNAs are well
characterized as post-transcriptional regulators of mRNAs and have well established roles in cancer
(Garzon et al., 2009; Fabian and Sonenberg, 2012; Kong et al., 2012).
On the other hand, lncRNAs still remain poorly characterized, however, evidence for their
importance and functionality is mounting. The number of known lncRNA genes is still rising as
the process of their annotation is ongoing. The current version of GENCODE (encyclopedia of
genes and gene variants) includes 15,877 human lncRNA genes encoding 26,414 transcripts based
on manual curation, computational analysis, and experimental validation (Version 21, June 2014
freeze, GRCh38 – Ensembl 77; Dunham et al., 2012; www.gencodegenes.org).
Long noncoding RNAs share common features with mRNAs, such as many of them are tran-
scribed by RNA polymerase II, undergo splicing, polyadenylation, and 5′-capping (Table 1).
Similarly, to protein coding genes, lncRNA genes have histone marks of active promoters
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TABLE 1 | Comparison of several important features of mRNAs and long
noncoding RNAs (lncRNAs) based on GENCODE v7 catalog of human
transcripts*.
Feature mRNAs lncRNAs
Median transcript length 2453 nt 592 nt
Median number of exons 3 8
Expression levels Higher Lower
5’ end supported by CAGE 55% 15%
3’ end supported by polyA signal 51% 39%
Tissue specificity Lower Higher
Subcellular localization Mostly cytoplasmic Mostly nuclear
∗The data shown in Table 1 are taken from Derrien et al. (2012).
(H3K4me2/3, H2K9ac, H3K27ac) and actively transcribed gene
bodies (H3K36me3; Guttman et al., 2009; Derrien et al., 2012).
On the other hand, lncRNAs have several distinct features
that distinguish them from protein coding mRNAs (Table 1).
LncRNAs generally lack or have very little open reading frames
(ORFs). Commonly, lncRNA transcripts are shorter and have
fewer exons. Unlike mRNAs, which are mostly transported to the
cytoplasm, the majority of lncRNAs are localized to the nucleus
(Derrien et al., 2012). LncRNAs demonstrate relatively lower
expression levels than protein coding genes, however, they exhibit
more speciﬁc tissue expression patterns (Derrien et al., 2012).
Contrary to the initial view that lncRNAs might be a mere
transcriptional noise, several lines of evidence indicate to their
functionality (Ponting and Belgard, 2010). Firstly, many lncR-
NAs demonstrate clear signs of evolutionary conservation and
selection (Ponjavic et al., 2007; Guttman et al., 2009). Secondly,
expression of many lncRNAs is developmentally and temporally
regulated and restricted to certain tissues (Cawley et al., 2004;
Ravasi et al., 2006; Mercer et al., 2008). It is becoming increasingly
clear that lncRNAs are important regulatory molecules acting at
diﬀerent levels of gene expression, such as chromatin remod-
eling, transcription, stability, posttranscriptional modiﬁcations,
and translation. For example, lncRNAs Xist and HOTAIR (HOX
transcript antisense RNA) recruit chromatin remodeling com-
plexes, such as Polycomb repressive complex 2 (PRC2) to induce
heterochromatin state, thus repressing gene expression at target
loci (Zhao et al., 2008; Gupta et al., 2010; Figure 1). Indeed, a
considerable proportion of lncRNAs has been shown to asso-
ciate with PRC2 complex, implying that it might be one of the
prevalent mechanisms for their functionality (Khalil et al., 2009).
LncRNAs directly regulate transcription by diﬀerent mecha-
nisms, such as via interaction with RNA binding proteins (Wang
et al., 2008), repression of promoters (Martianov et al., 2007), act-
ing as co-activators of transcription factors (Feng et al., 2006),
or negatively regulating transcription factors by sequestration
(Kino et al., 2010; Hung et al., 2011). At the level of pre-mRNA
processing, lncRNA MALAT1 can regulate alternative splicing
by interacting with several serine/arginine (SR) splicing factors
(Tripathi et al., 2010).
Long noncoding RNAs can interact with mRNAs and modu-
late their translation both positively and negatively. For exam-
ple, lincRNA-p21 interacts with JUNB and CTNNB1 mRNAs
and selectively lowers their translation through a mechanism
FIGURE 1 | Model of long noncoding RNA (lncRNA) HOX transcript
antisense RNA (HOTAIR) regulating expression of HOX genes in trans.
LncRNA HOTAIR transcribed from the HOXC cluster of genes (chr. 2) binds
PRC2 complex of polycomb-group of proteins and targets it to the HOXD
cluster (chr. 12) leading to H3K27 methylation and silencing of neighboring
HOXD genes. This figure is adapted from Rinn et al., 2007.
that includes reduced polysome sizes or ribosome ‘drop-oﬀ’
(Yoon et al., 2012). In contrast, lncRNA antisense to Uchl1 gene
increases translation of UCHL1 protein in a mechanism depen-
dent on a 5′ overlapping sequence and an embedded inverted
SINEB2 element in lncRNA (Carrieri et al., 2012). LncRNA can
also regulate stability of target mRNAs through imperfect base
pairing between an Alu element in the 3′ UTR of a Staufen 1
(STAU1)-mediated mRNA decay target and another Alu element
in a cytoplasmic lncRNA (Gong and Maquat, 2011). This imper-
fect base-pairing creates a lncRNA–mRNA duplex that binds
STAU1 resulting in degradation of mRNA.
With the growing evidence of lncRNA functionality it is of
no surprise that they are implicated in diverse pathologic condi-
tions, including cancer. Various lncRNAs have been found to be
diﬀerentially expressed in cancer and their enforced expression
or knock down could result in altered phenotypical responses
related tomalignant transformation, such as changes in prolifera-
tion, invasive potential, or apoptosis. Similarly, to protein coding
genes, lncRNAs can be classiﬁed into oncogenes and tumor sup-
pressors. This opens opportunities for application of lncRNAs
as biomarkers for cancer diagnosis and prognosis. Indeed, the
functions of lncRNAs are more likely to correlate with their
abundance as they do not encode proteins, making them highly
suitable as biomarkers. In this review, we summarize the current
knowledge about lncRNAs as potential diagnostic and prognostic
biomarkers of cancer.
Diagnostic Cancer Biomarkers
The tissue speciﬁc nature of expression of lncRNAs, which is gen-
erally higher than that of protein coding mRNAs (Derrien et al.,
2012), makes them potentially advantageous for identiﬁcation of
highly speciﬁc diagnostic biomarkers. Whereas some well known
lncRNAs, such as HOTAIR are known to be deregulated in a wide
spectrum of cancers, several lncRNAs have been described to be
highly speciﬁc for a particular cancer type.
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For example, expression of lncRNA PCA3 (Prostate Cancer
Antigen 3) is highly restricted to prostate tissue (Bussemakers
et al., 1999). In the same study it was shown by diﬀerential
display analysis that PCA3 is highly overexpressed in prostatic
tumors in comparison with non-neoplastic prostatic tissue of the
same patients. Moreover, its expression was not detected in other
tumor types or cell lines (Bussemakers et al., 1999). PCGEM1 is
another lncRNA gene with highly prostate tissue-speciﬁc expres-
sion. Interestingly, its elevated expression was associated with
high risk groups, such as the African–American population,
which is more susceptible to prostate cancer as compared to
Caucasian–American or those individuals with family history
of prostate cancer as compared to those without family his-
tory (Petrovics et al., 2004). Another lncRNA, encoded in 8q24
locus reported to be associated with prostate cancer suscepti-
bility in European and African–American populations, termed
PRNCR1 (prostate cancer noncoding RNA 1), was shown to be
up-regulated in some of the prostate cancer cells as well as pre-
cursor lesion prostatic intraepithelial neoplasia (Chung et al.,
2011).
HULC (highly up-regulated in liver cancer) has been identi-
ﬁed as highly up-regulated in hepatocellular carcinoma (Panzitt
et al., 2007) and colorectal carcinomas that produce liver metas-
tases but not in the primary colon tumors or their non-liver
metastases (Matouk et al., 2009). Interestingly, the speciﬁc genetic
variant rs7763881 in HULC was found to be associated with
decreased risk of HCC in persistent carriers of HBV (Liu et al.,
2012).
Detection of cancer at the early stages signiﬁcantly increases
the chances of successful therapy. One of the ways for early diag-
nosis is the screening for biomarkers by non-invasive methods,
such as sampling of extracellular ﬂuids. A fraction of DNA and
RNA molecules referred to as circulating nucleic acids (CNAs)
are found in blood serum and other extracellular ﬂuids. Changes
in the levels of CNAs are associated with tumor burden and
malignant progression, thus pointing to their potential as tumor
biomarkers easily detected by PCR assays (Schwarzenbach et al.,
2011). Several lncRNAs have been characterized as potential
biomarkers in human body ﬂuids. The most prominent exam-
ple of such biomarkers is PCA3, a lncRNA highly expressed is
prostate cancer (de Kok et al., 2002). The detection of PCA3 in
the urine has been demonstrated to be a more speciﬁc marker
to diagnose prostate cancer than the commonly used prostate-
speciﬁc antigen (PSA) and already found wide application in
clinics (Hessels et al., 2003; Tinzl et al., 2004; Lee et al., 2011).
Similarly, UCA1 (urothelial carcinoma associated 1) transcript
detected in urine was shown to be a highly sensitive and speciﬁc
biomarker of bladder carcinoma (Wang et al., 2006). HULC was
detected with high frequency in plasma of patients with hepato-
cellular carcinoma, making it a promising diagnostic biomarker
for this type of cancer (Xie et al., 2013). Several other studies iden-
tify promising biomarkers for diﬀerent types of cancer, such as
MALAT1 derived fragment detected in plasma as a biomarker for
prostate cancer (Ren et al., 2013), AA174084 found in gastric juice
as indicator of gastric cancer (Shao et al., 2014), a set of salivary
lncRNAs as potential markers for oral squamous cell carcinoma
diagnosis (Tang et al., 2013).
Exosomes are nanovesicles secreted into the extracellular envi-
ronment from the cells upon fusion of intracellular vesicles
with the plasma membrane (Raposo and Stoorvogel, 2013). The
molecular content of exosomes replicates that of the releasing cell
and reﬂects its status. The abundance of exosomes in body ﬂuids
and possibility to detect tumor speciﬁc material of their parental
cancer cells makes exosomes a promising tool for non-invasive
diagnostics (Properzi et al., 2013). The content of exosomes com-
prises diﬀerent kinds of RNA, including lncRNAs (Jenjaroenpun
et al., 2013). Indeed, lncRNAs are highly enriched in exosomes
compared to donor cells (Batagov et al., 2011; Gezer et al., 2014).
For example, lncRNA TUC339 was found to be highly enriched
in extracellular vesicles secreted from hepatocellular carcinoma
cells where it modulated tumor cell growth and adhesion (Kogure
et al., 2013). LincRNA–ROR, another lncRNA from hepatocellu-
lar carcinoma derived extracellular vesicles was shown to modu-
late chemotherapeutic response in this type of cancer (Takahashi
et al., 2014). Given the fact that most transcriptome studies aimed
to identify biomarkers were focused on miRNAs, shifting the
focus to more unbiased characterization that would include other
types of transcripts present in cancer derived exosomes would
potentially lead to discovery of more lncRNA based biomarkers.
Prognostic Cancer Biomarkers
Diﬀerent lncRNAs were shown to be aberrantly expressed in
cancer and correlate with tumorigenesis, tumor progression,
and metastatic properties in various cancer conditions. Such
lncRNA can be involved in both oncogenic and tumor suppres-
sor pathways and their expression can correlate with good or
bad prognosis, making them promising prognostic biomarkers
(Table 2).
HOTAIR is one of the most well studied examples of lncRNA
implicated in cancer (Wu et al., 2014a). Initially it was identiﬁed
by Gupta et al. (2010) to be highly overexpressed in primary and
metastatic breast cancer tissues as compared to normal breast
epithelium. High HOTAIR expression level in primary tumors
was shown to be a signiﬁcant predictor of eventual metastasis and
death (Gupta et al., 2010). Enforced expression of HOTAIR in
breast carcinoma cells induced genome wide retargeting of PRC2
and, as a result, altered H3K27 methylation and gene expres-
sion patterns, increased invasiveness, andmetastasis (Gupta et al.,
2010). Interestingly, BRCA1, an important suppressor of breast
cancer inhibits HOTAIR dependent PRC2 activity by competi-
tive binding to its catalytic subunit EZH2 (Wang et al., 2013). In
another breast cancer study it was shown that HOTAIR is regu-
lated by oestradiol in estrogen receptor dependent manner (Bhan
et al., 2013).
HOTAIR was also shown to be involved in hepatocellular car-
cinoma (Geng et al., 2011; Yang et al., 2011; Ishibashi et al., 2013).
Overexpression of HOTAIR in tumor tissues was reported to be
associated with increased risk of recurrence after hepatectomy,
as well as positively correlate with lymph node metastasis (Geng
et al., 2011). Similarly, increased HOTAIR was shown to be prog-
nostic factor of tumor recurrence following liver transplantation
(Yang et al., 2011). In the same study, knock down of HOTAIR
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TABLE 2 | lncRNAs with cancer biomarker potential.
lnc-RNA Cancer type Reference Oncogene
Tumor suppressor
Biomarker usability potential
HOTAIR Breast Gupta et al. (2010), Bhan et al. (2013), Wang et al. (2013) Oncogene Predictor of metastasis and poor survival
Liver Geng et al. (2011), Yang et al. (2011), Ishibashi et al. (2013) Oncogene Predictor of recurrence and poor survival
Colorectal Kogo et al. (2011) Oncogene Predictor of liver metastasis and pool survival
Gastric Hajjari et al. (2013) Oncogene Predictor of lymph node metastasis
Pancreas Kim et al. (2013) Oncogene Predictor of poor survival
Lung Liu et al. (2013a), Nakagawa et al. (2013) Oncogene Predictor of metastasis and poor survival
Esophagus Lv et al. (2013) Oncogene Predictor of metastasis and poor survival
Cervical Huang et al. (2014) Oncogene Predictor of metastasis and poor survival
MALAT1 Lung adenocar-
cinoma
Ji et al. (2003), Gutschner et al. (2013) Oncogene Predictor of metastasis and poor survival
Liver Lai et al. (2012) Oncogene Predictor of recurrence after liver transplantation
Colorectal Zheng et al. (2014) Oncogene Predictor of poor postoperative prognosis
Cervical Guo et al. (2010) Oncogene
Bladder Ying et al. (2012), Han et al. (2013) Oncogene Predictor of metastasis
Uterine Yamada et al. (2006) Oncogene
Osteosarcoma Fellenberg et al. (2007) Oncogene Predictor of poor response to chemotherapy
H19 Esophagus Hibi et al. (1996) Oncogene
Breast Lottin et al. (2002) Oncogene
Lung Kondo et al. (1995) Oncogene
Bladder Ariel et al. (2000) Oncogene
Ovarian Kim et al. (1998) Oncogene
Cervical Kim et al. (2002) Oncogene
Osteosarcoma Ulaner et al. (2003) Oncogene
Neck squamous
carcinoma
el-Naggar et al. (1999) Oncogene
Liver Matouk et al. (2007) Oncogene
ncRAN Neuroblastoma Bown et al. (1999), Yu et al. (2009) Oncogene Predictor of poor survival
Bladder Zhu et al. (2011) Oncogene
Colorectal Qi et al. (2014) Tumor suppressor Low level predicts poor survival
HULC Liver Panzitt et al. (2007), Matouk et al. (2009), Liu et al. (2012) Oncogene Diagnostics
GAS5 Breast Mourtada-Maarabouni et al. (2009) Tumor suppressor
Kidney Qiao et al. (2013) Tumor suppressor
Pancreas Lu et al. (2013) Tumor suppressor
Bladder Liu et al. (2013b) Tumor suppressor
Lung Shi et al. (2013) Tumor suppressor
Gastric Sun et al. (2014) Tumor suppressor Low level predicts poor prognosis
Pleural
mesothelioma
Renganathan et al. (2014) Tumor suppressor Low level predicts poor prognosis
Liver Tu et al. (2014) Tumor suppressor Low level predicts poor prognosis
PCA3 Prostate Bussemakers et al. (1999), Hessels et al. (2003) Oncogene Non-invasive diagnosis by sampling urine or
bloodTinzl et al. (2004), Lee et al. (2011)
UCA1 Bladder Wang et al. (2006) Oncogene Non-invasive diagnosis by sampling urine
PCGEM1 Prostate Petrovics et al. (2004) Oncogene High risk predictor
PRNCR1 Prostate Chung et al. (2011) Oncogene High risk predictor
MEG3 Leukemia Benetatos et al. (2010) Tumor suppressor CpG methylation predicts poor survival
Pituitary
adenoma
Gejman et al. (2008) Tumor suppressor
Meningioma Zhang et al. (2010) Tumor suppressor Loss associated with progression
Glioma Wang et al. (2012) Tumor suppressor
NBAT-1 Neuroblastoma Pandey et al. (2014) Tumor suppressor Loss associated with progression
LincRNA–ROR Liver Takahashi et al. (2014) Oncogene Diagnostics by sampling cancer exosomes;
indicator of chemoresistance
PCAT1 Prostate Prensner et al. (2011) Oncogene Associated with progression
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in HCC cell line reduced cell viability and invasion, as well as
increased sensitivity to cisplatin and doxorubicin (Yang et al.,
2011). Patients with overexpressed HOTAIR had poorer prog-
noses and larger tumor sizes, more rapid proliferation of tumor
cells (Ishibashi et al., 2013).
In colorectal carcinoma high expression of HOTAIR was also
shown to correlate with poor prognosis and liver metastasis
(Kogo et al., 2011). Positive correlation between expression lev-
els of HOTAIR, the members of PRC2 complex, Suz12, and Ezh2,
and H3K27me3 chromatin marks suggests the role of HOTAIR in
PRC2 mediated chromatin reprogramming in metastasis (Kogo
et al., 2011). Apart from the primary tumors, HOTAIR was also
shown to be a negative prognostic factor in the blood of col-
orectal patients suggesting that measuring the HOTAIR blood
levels may provide a minimally invasive test to identify patients
with unfavorable prognosis (Svoboda et al., 2014). High expres-
sion of HOTAIR associated with advanced stage, lymphatic node
metastasis and poor survival was also reported in gastric can-
cer (Endo et al., 2013; Hajjari et al., 2013; Xu et al., 2013).
The increased expression level of HOTAIR positively correlates
with Suz12, implying PRC2 dependent mechanism of epigenetic
reprogramming in oncogenicity of gastric carcinoma (Hajjari
et al., 2013). Also HOTAIR was shown to act as an endoge-
nous sponge of miR-331-3p miRNA, thus abolishing repression
of its target HER2, implicated in development of gastric cancer
(Liu et al., 2014). In addition to the above described, HOTAIR
was reported to be a negative prognosis biomarker for a num-
ber of other malignancies, such as pancreatic cancer (Kim et al.,
2013), lung cancer (Liu et al., 2013a; Nakagawa et al., 2013),
esophageal carcinoma (Lv et al., 2013), cervical cancer (Huang
et al., 2014), and colon cancer (Wu et al., 2014b). A meta-analysis
study of prognostic capability of HOTAIR in diﬀerent types of
cancer revealed that it is a more reliable predictor of overall sur-
vival in patients with digestive system malignancies (Zhang et al.,
2014).
Another paradigmal case of lncRNA based cancer biomark-
ers is MALAT1 (Metastasis-associated Lung Adenocarcinoma
Transcript 1). As its name implies, it was discovered as a
predictive marker of metastasis development in early stage
lung adenocarcinoma (Ji et al., 2003). In a MALAT1 knock-
out model of human lung cancer cells it was shown that
MALAT1 regulates metastatic signature of genes (Gutschner
et al., 2013). In such model metastatic capacities of lung
adenocarcinoma mouse xenografts were signiﬁcantly compro-
mised (Gutschner et al., 2013). In the same study, targeting
MALAT1with antisense nucleotides signiﬁcantly reduced metas-
tasis making it an interesting target for therapy (Gutschner et al.,
2013).
In hepatocellular carcinoma (HCC) MALAT1 overexpression
is a predictive factor for tumor recurrence following liver trans-
plantation (Lai et al., 2012). The depletion of MALAT1 by siRNA
in HepG2 cell line resulted in reduction of cell viability, mobility
and invasiveness, as well as increase of sensitivity to apopto-
sis (Lai et al., 2012). High expression of MALAT1 was shown
to be a marker of poor postoperative prognosis in colorectal
carcinoma (Zheng et al., 2014). Moreover, the obvious onco-
genic role of MALAT1 was demonstrated in a number of other
cancer models, including bladder cancer (Ying et al., 2012; Han
et al., 2013), cervical cancer (Guo et al., 2010), uterine sar-
coma (Yamada et al., 2006), and osteosarcoma (Fellenberg et al.,
2007).
H19 is lncRNA expressed from thematernal allele that plays an
important role in genomic imprinting during growth and devel-
opment (Gabory et al., 2010). Loss of imprinting at the H19
locus in paternal allele results in biallelic expression and, there-
fore, elevated H19 levels in a wide range of cancers (Kondo et al.,
1995; Hibi et al., 1996; Kim et al., 1998; el-Naggar et al., 1999;
Ariel et al., 2000; Müller et al., 2000; Kim et al., 2002; Lottin
et al., 2002; Ulaner et al., 2003). High expression of H19 was
shown to be associated with a range of risk factors, such as smok-
ing, exposure to carcinogens and hypoxia (Matouk et al., 2007).
Indeed, hypoxia causes up-regulation of H19 in cell lines with
mutated p53 (Matouk et al., 2010). H19 is also directly induced
by MYC oncogene in diﬀerent cell lines (Barsyte-Lovejoy et al.,
2006). Further adding to the host of oncogenic pathways with
the involvement of H19, it serves as a precursor of miR-675,
miRNA that down-regulates RB1 tumor suppressor transcript in
colorectal cancer (Tsang et al., 2010).
NcRAN (noncoding RNA expressed in aggressive neurob-
lastoma) is encoded by a gene mapped to chromosome arm
17q, whose ampliﬁcation is one of the most common genetic
abnormalities associated with poor prognosis in neuroblastoma
(Bown et al., 1999; Yu et al., 2009). Indeed, the high expres-
sion levels of ncRAN were signiﬁcantly associated with poor
prognosis of the neuroblastoma patients (Yu et al., 2009). In
addition, ncRAN was found to be upregulated in bladder can-
cer as compared to normal tissues and confer a set of onco-
genic properties, such as increased cell proliferation, migration,
and invasion (Zhu et al., 2011). In contrast, down-regulation of
ncRAN was shown to be associated with metastatic properties
and predict poor overall survival in colorectal carcinoma (Qi
et al., 2014).
In addition to lncRNAs with pronounced oncogenic eﬀects,
which positively correlate with poor prognosis, a few lncRNAs
have been characterized to act as tumor suppressors. One such
example is GAS5 (growth arrest-speciﬁc 5), a tumor suppressor
lncRNA which reduces growth, metabolism, and sensitizes cells
to apoptosis by inhibiting glucocorticoid receptor (Kino et al.,
2010). GAS5 is down-regulated in a number of cancers, such as
breast cancer (Mourtada-Maarabouni et al., 2009), renal cell car-
cinoma (Qiao et al., 2013), pancreatic cancer (Lu et al., 2013),
bladder cancer (Liu et al., 2013b), non-small-cell lung cancer
(Shi et al., 2013), gastric cancer (Sun et al., 2014), malignant
pleural mesothelioma (Renganathan et al., 2014), hepatocellu-
lar carcinoma (Tu et al., 2014). Low level of GAS5 indicates a
poor prognosis in cancer patients (Sun et al., 2014; Tu et al.,
2014).
Another example of a tumor suppressor lncRNA is lincRNA-
p21. This lncRNA was shown to be directly induced by p53
and play a crucial role in p53 mediated transcriptional response
(Huarte et al., 2010). Maternally expressed gene 3 (MEG3)
is another prominent tumor suppressor lncRNA that acts by
increasing p53 activity on speciﬁc transcription targets (Zhou
et al., 2007). Besides, MEG3 is able to inhibit cell proliferation
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in the absence of p53 suggesting that this lncRNA may act also
via p53-independent pathway (Zhou et al., 2007). Consistently,
MEG3 is down-regulated in a number of cancers, including
myeloid leukemia (Benetatos et al., 2010), pituitary adenoma
(Gejman et al., 2008), meningioma (Zhang et al., 2010), and
glioma (Wang et al., 2012).
In conclusion, lncRNAs may act both as oncogenes and tumor
suppressors without obvious prevalence of one class over another.
In this respect lncRNAs behave similarly, to protein-coding tran-
scripts.
Prognostic Expression Signatures
Based on lncRNAs
Characterizing tumor transcriptomes at the system’s level allows
identiﬁcation of molecular subtypes of cancer and develop-
ment of predictive and prognostic gene expression signatures.
Microarrays have been widely used for the past two decades in
preclinical research to characterize tumor gene expression pro-
ﬁles on a genome-wide scale. Most of these signatures were
based on protein coding genes as little was known about lncR-
NAs and their important roles in cancer. However, the widely
used commercial microarray platforms in addition to protein
coding mRNAs were designed to detect numerous ESTs and non-
annotated RNAs. Many of these transcripts are now annotated
as bona fide lncRNAs, therefore the vast collection of microar-
ray datasets accumulated during the past two decades provides
a valuable resource for identiﬁcation of novel gene expression
signatures and biomarkers based on lncRNAs. In our recent
study we annotated probe sets detecting lncRNAs on widely used
Aﬀymetrix U133 series of microarray platforms by using two
approaches: ﬁrstly by matching probe sets to Gencode database
of lncRNAs and secondly by developing a stringent in silico pro-
tein coding potential prediction ﬁlter (Yarmishyn et al., 2014).
Aﬀymetrix U133 microarrays have been found to contain probe
sets for the measurement of 1581 lncRNAs (Yarmishyn et al.,
2014). Using this resource and previously deposited microarray-
based data on expression proﬁling of neuroblastic tumors we
identiﬁed 159 lncRNA signature that discriminates between
localized and metastatic stages of neuroblastoma, as well as
between relapsing and non-relapsing primary tumors (Yarmishyn
et al., 2014). The data mining of Aﬀymetrix U133 Plus datasets
was also applied to identify lncRNA signatures associated with
diﬀerent histological subtypes and malignancy grades of glioma
(Zhang et al., 2012). In the follow up study, the six-lncRNA prog-
nostic signature of glioma signiﬁcantly associated with overall
survival was identiﬁed (Zhang et al., 2013). In another study
the classiﬁcation of glioma into three molecular subtypes based
on lncRNA expression proﬁles was proposed (Li et al., 2014).
Similarly, using lncRNA mining approach, Hu et al. (2014) iden-
tiﬁed six lncRNA prognostic signature signiﬁcantly associated
with disease free survival in colorectal carcinoma. LncRNA-based
expression proﬁles were also utilized to classify colorectal cancer
samples into ﬁve distinct molecular subtypes, each characterized
by distinct biological pathways and clinical outcome (Chen et al.,
2014).
As high throughput sequencing technology becomes cheaper
and more accessible we might expect the inﬂux of de novo
data from transcriptome sequencing and identiﬁcation of new
biomarkers and diagnostic signatures. For example, Prensner
et al. (2011) utilized RNA-Seq approach to identify 121 lncR-
NAs associated with prostate cancer progression in a cohort of
102 patients. One of these lncRNAs PCAT-1 was further char-
acterized as a regulator of proliferation in prostate cancer cells
(Prensner et al., 2011). In a similar study the sequencing of tran-
scriptomes of high and low risk neuroblastoma identiﬁed a set
of diﬀerentially expressed lncRNAs. One of them NBAT-1 was
characterized as a tumor suppressor, whose loss contributes to
aggressive neuroblastoma by increasing proliferation and impair-
ing diﬀerentiation (Pandey et al., 2014). RNA-Seq analysis was
also employed by White et al. (2014) to detect lncRNAs associ-
ated with lung cancer. In this study the transcriptome sequencing
data from a cohort of 567 patients were used to identify 111
novel lncRNAs diﬀerentially regulated between tumor and adja-
cent normal tissue samples. Further meta-analysis revealed that
a subset of these lncRNAs was deregulated in a broad range of
tumors and another subset was highly deregulated speciﬁcally in
lung cancers, making the latter a promising source of biomarkers
(White et al., 2014).
Concluding Remarks
The last decade witnessed a vast expansion of knowledge regard-
ing lncRNAs and their important roles in regulation of various
biological processes and development of disease. A number of
lncRNAs, such as HOTAIR, MALAT and H19 were found to
be aberrantly expressed in a number of cancers and exten-
sively characterized as important players aﬀecting the hallmark
events of carcinogenesis, such as proliferation, apoptosis, and
metastasis. These examples demonstrate that lncRNAs, on par
with protein coding genes and miRNAs, have a great poten-
tial to be used as cancer biomarkers. Indeed, since lncRNAs
are implicated in cancer biology at the level of RNA unlike
mRNAs, which represent an intermediate on the way to func-
tioning protein, their levels of expression are more likely to
correlate with cancer phenotypes. Also, since proteins and lncR-
NAs represent diﬀerent regulatory realms, their combination
might increase each other’s power as diagnostic and prognos-
tic tools. It should be noted that the few examples described in
this review are just a tip of the iceberg, as the ﬁeld of lncRNAs
is currently evolving and the work of annotation and charac-
terization of lncRNAs is ongoing. With the deep sequencing
technology becoming cheaper and more accessible one might
expect an explosive growth of newly identiﬁed lncRNAs diﬀer-
entially expressed in cancers and associated with various clinical
parameters.
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